Twist Bioscience(NASDAQ) TWST

Twist makes synthetic DNA for scientists and drug researchers. Its technology helps laboratories study diseases and find new medicines. The company uses silicon chips to build DNA sequences.

Writing the Code of Life

• NGS applications: Tools used to prepare biological samples for Next Generation Sequencing, which identifies the order of DNA building blocks; accounts for 51% of revenue.
• DNA synthesis and protein solutions: Customized synthetic genes and antibody libraries used to discover new drugs; accounts for 49% of revenue.
• Biopharma services: Discovery partnerships that help pharmaceutical companies identify therapeutic antibodies against specific medical targets.

Recent Strategic Moves

• Sold the DNA digital data storage business in 2025 to focus on core synthesis and sequencing operations.
• Entered a research collaboration with Boehringer Ingelheim International GmbH to discover therapeutic antibodies using proprietary libraries.
• Amended a lease in November 2025 to expand and consolidate its South San Francisco headquarters into one location.
• Partnered with groups like Victorian Clinical Genetic Services and Centogene N.V to develop advanced genetic sequencing tools.

What Sets Twist Apart?

Twist uses silicon chips instead of traditional plastic plates to manufacture DNA with higher precision and lower costs. Its integrated e-commerce platform allows customers to design, order, and track custom genetic sequences entirely online.

Twist by the Numbers

• Revenue grew to $103.7 million in Q1 2026, a 16.9% increase compared to the prior year.
• Gross profit reached $54 million in Q1 2026, up 26% from $42.8 million in Q1 2025.
• Gross margin improved to 52% in Q1 2026, up from 48.3% during the same period in 2025.
• Operating loss narrowed to $32.9 million in Q1 2026, a 5% improvement over the previous year.
• Cash, equivalents, and short-term investments totaled $197.9 million as of December 31, 2025.

Evolution of the Platform

Twist has evolved from a DNA component supplier into a broader provider of biological solutions and pharmaceutical discovery services. The shift toward higher-value protein and sequencing applications supports its strategy for margin improvement and operational efficiency.